Skip to content
Screener

Denali Therapeutics Inc. DNLI Q2 2025 earnings

Reported August 11, 2025 · Before market open

Revenue-
EPS-$0.72Beat by $0.02
EPS estimate-$0.74

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$12.2M
EPS estimate-$0.37

Financials

Q2 2025

Income statement

See full
Revenue-—
Gross profit-—
Operating income-$135.0M-15.8%
Net income-$124.1M-25.3%
EPS (diluted)-$0.72-22.0%

Balance sheet

See full
Cash & equivalents$144.3M+89.3%
Total debt$48.0M-1.6%
Total equity$1.0B-26.0%
Total assets$1.2B-22.4%

Cash flow

See full
Operating cash flow-$75.3M+17.5%
CapEx$4.3M-10.6%
Free cash flow-$79.6M+17.1%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$2.09B-36.8%
Enterprise value$2B-39.2%

Returns & leverage

See full
Return on equity-39.7%+11.0pp
Debt / equity0×0.0×
Current ratio10.3×-2.2×

Segments

By product

See full
Milestone Triggered$25.0M—
CNS Product$16.3M—
Milestone Payment$2.5M—
Option Fee Payment$1.3M—

By segment

See full
Therapeutics Segment-—

FAQ

When did Denali Therapeutics Inc. report Q2 2025 earnings?
Denali Therapeutics Inc. (DNLI) reported Q2 2025 earnings on August 11, 2025 before market open.
What were Denali Therapeutics Inc.'s Q2 2025 revenue and EPS?
Denali Therapeutics Inc. reported revenue of - and eps of $-0.72 for Q2 2025.
Did Denali Therapeutics Inc. beat estimates in Q2 2025?
EPS beat the consensus estimate of $-0.74 by $0.02.
How did Denali Therapeutics Inc.'s Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 22.0% from $-0.59.
Where can I find Denali Therapeutics Inc.'s Q2 2025 SEC filings?
You can read the 8-K earnings release (0001714899-25-000167) and the 10-Q periodic report (0001714899-25-000170) directly on SEC EDGAR. The filing index links above go to sec.gov.